Harald Fricke
Chief Tech/Sci/R&D Officer at Apogenix AG
Profile
Harald Fricke is a professional with a doctorate degree from RWTH Aachen University and Universität zu Lübeck.
He is currently the Chief Medical Officer at Apogenix AG since 2006.
Prior to this, he held positions as Vice President-Global Clinical Development at Neovii Biotech GmbH, and as Principal at GlaxoSmithKline GmbH & Co. KG and SmithKline Beecham Pharma GmbH & Co. KG.
Harald Fricke active positions
Companies | Position | Start |
---|---|---|
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Chief Tech/Sci/R&D Officer | 2005-12-31 |
Former positions of Harald Fricke
Companies | Position | End |
---|---|---|
GlaxoSmithKline GmbH & Co. KG
GlaxoSmithKline GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline GmbH & Co. KG is a German pharmaceutical company. The company is based in Munich, Germany. The CEOs of the company are Jean-Bernard Siméon, Adrian Bauer. | Corporate Officer/Principal | - |
SmithKline Beecham Pharma GmbH & Co. KG
SmithKline Beecham Pharma GmbH & Co. KG Pharmaceuticals: MajorHealth Technology SmithKline Beecham Pharma GmbH & Co. KG is a manufacturer of pharmaceuticals. The company was founded in 1989 and is headquartered in Munich, Germany, with manufacturing facilities within the country. | Corporate Officer/Principal | - |
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Corporate Officer/Principal | - |
Training of Harald Fricke
RWTH Aachen University | Doctorate Degree |
Universität zu Lübeck | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |
GlaxoSmithKline GmbH & Co. KG
GlaxoSmithKline GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline GmbH & Co. KG is a German pharmaceutical company. The company is based in Munich, Germany. The CEOs of the company are Jean-Bernard Siméon, Adrian Bauer. | Health Technology |
SmithKline Beecham Pharma GmbH & Co. KG
SmithKline Beecham Pharma GmbH & Co. KG Pharmaceuticals: MajorHealth Technology SmithKline Beecham Pharma GmbH & Co. KG is a manufacturer of pharmaceuticals. The company was founded in 1989 and is headquartered in Munich, Germany, with manufacturing facilities within the country. | Health Technology |
- Stock Market
- Insiders
- Harald Fricke